| Grant ID | RP240441 |
| Awarded On | August 21, 2024 |
| Title | Precision Lung Cancer Interception by Targeting High-Risk Lung Nodules |
| Program | Academic Research |
| Award Mechanism | Clinical Investigator Award |
| Institution/Organization | The University of Texas M.D. Anderson Cancer Center |
| Principal Investigator/Program Director | Jianjun Zhang |
| Cancer Sites | Lung and Bronchus |
| Contracted Amount | $1,098,945 |
| Lay Summary |
As the leading cancer killer globally, lung cancer's complexity makes it challenging to cure. Effective strategies for preventing the development of invasive lung cancers are crucial. As an oncologist at MD Anderson, my research team discovered that precancers have simpler molecular structures, making them more manageable to eradicate. We initiated two clinical trials, Can-Prevent-Lung and IMPRINT-Lung, to reprogram the immune cells and treat these early stages, a concept known as interception. Early results from Can-Prevent-Lung show promising activities and a good safety profile, suggesting that lung cancer interception could reshape the future of this disease. I am committed to transla... |